Nidanilimab (CAN04)是一种完全人源化的抗IL1RAP单克隆抗体，可通过阻断IL1α/β信号通路及刺激免疫系统以杀伤肿瘤细胞，目前正用于非小细胞肺癌与胰腺导管腺癌的相关研究。

[1] Rydberg Millrud C, Deronic A, Grönberg C, Jaensson Gyllenbäck E, von Wachenfeldt K, Forsberg G, Liberg D. Blockade of IL-1α and IL-1β signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapy. Cancer Immunol Immunother. 2023 Mar;72(3):667-678. doi: 10.1007/s00262-022-03277-3. Epub 2022 Aug 29. PMID: 36036818; PMCID: PMC10992377.[2]Millrud CR, et, al. The anti-IL1RAP antibody CAN04 increases tumor sensitivity to platinum-based chemotherapy.